Research & KnowledgeEvent: September 1, 2026
Oxford Nanopore Technologies research explores how nanopore sequencing could transform mRNA therapeutics quality control in GMP environments.
Published
Signal category
Research & Knowledge
Quote
“Amanda Hughes' research explores how nanopore sequencing could transform mRNA therapeutics QC in GMP environments.”
— Charlotte O'Farrell|Oxford Nanopore Technologies team
Company
Oxford Nanopore Technologies
Our goal is to enable the analysis of anything, by anyone, anywhere.
- Industry
- Biotechnology Research
- Location
- Oxford, GB
- Company size
- 1,368 employees
Oxford Nanopore Technologies plc was founded in 2005 as a spin-out from the University of Oxford. The company now employs more than 1000 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialisation. The management team, led by CEO Francis Van Parys, has a track record of delivering disruptive technologies to the market.